Needham Maintains Buy on AtriCure, Raises Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
Needham has maintained its Buy rating on AtriCure and raised the price target to $81, indicating confidence in the company's future performance.
April 28, 2021 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham has reiterated its Buy rating for AtriCure and increased the price target to $81, suggesting a positive outlook for the company's stock.
The increase in price target by Needham reflects a positive sentiment towards AtriCure's future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in ATRC's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100